Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

The pharmacogenomics journal - 1 Feb 2010

Laika B, Leucht S, Heres S, Schneider H, Steimer W

Abstract excerpt

Psychiatric pharmacotherapy with olanzapine is commonplace. We investigated the influence of CYP1A2*1F (-163A, rs762551) and serotonergic polymorphisms on olanzapine serum concentrations and clinical outcome in a naturalistic clinical setting. Included were 124 Caucasian psychiatric inpatients tr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodiazepines
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder

Share to Olanzapine

Share to Pharmacogenetics

Share to Receptor, Serotonin, 5-HT2A

Share to Receptor, Serotonin, 5-HT2C

Share to Weight Gain

Source

Identifiers

PMID: 19636338
DOI: 10.1038/tpj.2009.32

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19636338-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.PMID 19636338Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

Pharmacogenetics of AntipsychoticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.